Dose Reductions and Discontinuations with Chronic Lymphocytic Leukemia (CLL) Patients Receiving Ibrutinib in Community and Academic Settings

Jing-Zhou Hou; Kellie Ryan; Senxi Du; Bruno S. Fang; Stanley M. Marks; Ray Page; Eileen Peng; Keith Szymanski; Sharon Winters; Hannah Le

doi:10.1182/BLOOD-2020-139951

Dose Reductions and Discontinuations with Chronic Lymphocytic Leukemia (CLL) Patients Receiving Ibrutinib in Community and Academic Settings

Jing-Zhou Hou
, Kellie Ryan
, Senxi Du
, Bruno S. Fang
, Stanley M. Marks
, Ray Page
, Eileen Peng
, Keith Szymanski
, Sharon Winters
, Hannah Le

University of Pittsburgh
AstraZeneca
University of Southern California
Regional Cancer Care Associates, East Brunswick, NJ
The Center of Cancer and Blood Disorders, Fort Worth, TX

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Blood
Volume	136
DOIs	https://doi.org/10.1182/BLOOD-2020-139951
State	Published - Nov 5 2020
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1182/BLOOD-2020-139951License: Unspecified

Cite this

@article{46e60b0bb5f1421fae50ca0e88b8d0d9,

title = "Dose Reductions and Discontinuations with Chronic Lymphocytic Leukemia (CLL) Patients Receiving Ibrutinib in Community and Academic Settings",

author = "Jing-Zhou Hou and Kellie Ryan and Senxi Du and Fang, \{Bruno S.\} and Marks, \{Stanley M.\} and Ray Page and Eileen Peng and Keith Szymanski and Sharon Winters and Hannah Le",

note = "Oral and Poster Abstracts 905. Outcomes Research-Malignant Conditions (Lymphoid Disease): Poster I Therapies, Adverse Events, Study Population 1University of Pittsburgh Medical Center, Pittsburgh, PA 2AstraZeneca, Gaithersburg, MD 3Keck School of Medicine, Los Angeles, CA 4Regional Cancer Care Associates, East Brunswick, NJ 5The Center of Cancer and Blood Disorders, Fort Worth, TX 6 Quality Cancer Care Alliance Network, Tacoma, WA Introduction: Since its approval in 2014, ibrutinib has replaced chemotherapy to become a preferred therapy for CLL patients.",

year = "2020",

month = nov,

day = "5",

doi = "10.1182/BLOOD-2020-139951",

language = "American English",

volume = "136",

journal = "Blood",

publisher = "American Society of Hematology",

}

TY - JOUR

T1 - Dose Reductions and Discontinuations with Chronic Lymphocytic Leukemia (CLL) Patients Receiving Ibrutinib in Community and Academic Settings

AU - Hou, Jing-Zhou

AU - Ryan, Kellie

AU - Du, Senxi

AU - Fang, Bruno S.

AU - Marks, Stanley M.

AU - Page, Ray

AU - Peng, Eileen

AU - Szymanski, Keith

AU - Winters, Sharon

AU - Le, Hannah

N1 - Oral and Poster Abstracts 905. Outcomes Research-Malignant Conditions (Lymphoid Disease): Poster I Therapies, Adverse Events, Study Population 1University of Pittsburgh Medical Center, Pittsburgh, PA 2AstraZeneca, Gaithersburg, MD 3Keck School of Medicine, Los Angeles, CA 4Regional Cancer Care Associates, East Brunswick, NJ 5The Center of Cancer and Blood Disorders, Fort Worth, TX 6 Quality Cancer Care Alliance Network, Tacoma, WA Introduction: Since its approval in 2014, ibrutinib has replaced chemotherapy to become a preferred therapy for CLL patients.

PY - 2020/11/5

Y1 - 2020/11/5

UR - https://ash.confex.com/ash/2020/webprogram/Paper139951.html

U2 - 10.1182/BLOOD-2020-139951

DO - 10.1182/BLOOD-2020-139951

M3 - Article

VL - 136

JO - Blood

JF - Blood

ER -

Dose Reductions and Discontinuations with Chronic Lymphocytic Leukemia (CLL) Patients Receiving Ibrutinib in Community and Academic Settings

Disciplines

Access to Document

Other files and links

Cite this